UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): October 1, 2020
RenovaCare, Inc.
(Exact Name of Registrant as Specified in Charter)
Nevada | 000-30156 | 98-0384030 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
4 Becker Farm Road, Suite 105, Roseland, New Jersey 07068 |
(Address of Principal Executive Offices) (Zip Code) |
(888) 398-0202
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Section 5 Corporate Governance and Management
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(a) Departure of Directors or Certain Officers. On October 1, 2020, Harmel S. Rayat notified RenovaCare, Inc. (the “Company”) by letter that he would resign as a member of the Board of Directors (the “Board”) and as Chairman of the Board effective October 1, 2020. Mr. Rayat advised the Company that his resignation was not due to any disagreements between him and the Company on any matter relating to the Company's operations, policies or practices. The Board accepted Mr. Rayat’s resignation at a special meeting thereof held on October 1, 2020. In accordance with the requirements of Item 5.02 of Form 8-K, the Company has provided Mr. Rayat with a copy of the disclosures that it is making in response to this Item 5.02 no later than the date of filing this Form 8-K with the SEC and will provide Mr. Rayat with the opportunity to furnish the Company, as promptly as possible, with a letter addressed to the Company stating whether Mr. Rayat agrees with the statements made by the Company in response to this Item 5.02 and, if not, stating the respects in which he does not agree. On October 1, 2020, the Board elected Alan L. Rubino, the Company’s President and Chief Executive Officer and member of the Board, to also serve as the Company’s Chairman of the Board, until his successor shall have been duly elected or his earlier resignation or removal.
Section 7 Regulation FD
Item 7.01. Regulation FD Disclosure.
The Company issued a press release on October 5, 2020 announcing the director resignation described in Item 5.02(a) above. The press release making this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on October 6, 2020.
RenovaCare, Inc. | ||
By: | /s/ Alan L. Rubino | |
Alan L. Rubino | ||
President and Chief Executive Officer | ||
EXHIBIT 17.1
September 30, 2020
The Board of Directors
RenovaCare, Inc.
4 Becker Farm Road, Suite 105
Roseland, New Jersey 07068
Gentlemen,
Please be advised that I hereby tender my resignation as a Director and Chairman of the Board of RenovaCare, Inc., effective October 1 st, 2020.
Sincerely,
Harmel S. Rayat
EXHIBIT 17.2
Harmel S. Rayat
700 – 688 West Hastings Street
Vancouver, BC, V6B 1P1
October 1st, 2020
The Board of Directors
RenovaCare, Inc.
4 Becker Farm Road, Suite 105
Roseland, New Jersey 07068
Gentlemen,
Please note that my resignation as a member of the Board of Directors of RenovaCare, Inc. and as Chairman thereof, effective October 1, 2020, was not due to any disagreements between me and the Company on any matter relating to the Company’s operations, policies, or practices.
Sincerely,
Harmel S. Rayat
EXHIBIT 99.1
RenovaCare Elects Alan L. Rubino to Chairman of the Board of Directors
ROSELAND, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020. Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date.
Mr. Rubino was named President and CEO, and a member of the Company’s Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the Company on its planned transition from a pre-clinical stage to a development/commercial stage entity.
Mr. Rubino stated, “On behalf of the entire RenovaCare organization, I wish to thank Mr. Rayat for his many years of unwavering support and capital investment, crucial for the development of our CellMist and SkinGun regenerative technology platforms.”
Addressing his departure from the Company, Mr. Rayat commented, “In addition to making a significant investment to finance the development of the Company’s breakthrough technology, I endeavored to find a highly competent CEO that could take RenovaCare to the next level. Over the last year, Alan and his expanded management team have exceeded both the Board’s expectations and mine, and their extensive experience and wide-ranging capabilities have now allowed me to devote more time to my family office portfolio. As a long-time stockholder, I remain an ardent supporter of Alan and his entire team and look forward to the day that the SkinGun becomes the treatment of choice for patients everywhere suffering from severe burns and wounds.”
“We wish Mr. Rayat continued success in his future business endeavors,” concluded Mr. Rubino.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patient’s stem cells – the CellMist Solution – onto wounds.
RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
For additional information, please call Amit Singh at: 888-398-0202 or visit: https://renovacareinc.com
To receive future press releases via email, please visit:
https://renovacareinc.com/investors/register/
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
Follow us on Twitter: https://twitter.com/RenovaCareInc
Follow us on Facebook: https://www.facebook.com/renovacarercar
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.
We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
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